help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DONNELLY, R.
Right arrow Articles by SEALE, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DONNELLY, R.
Right arrow Articles by SEALE, J. P.

Am. J. Respir. Crit. Care Med., Volume 156, Number 6, December 1997, 1746-1751

Effects of Budesonide and Fluticasone on 24-Hour Plasma Cortisol
A Dose-Response Study

RICHARD DONNELLY, KENNETH M. WILLIAMS, A. BARRY BAKER, CARO-ANNE BADCOCK, RICHARD O. DAY, and J. PAUL SEALE

Department of Pharmacology, University of Sydney; Department of Clinical Pharmacology, St. Vincent's Hospital, and The University of New South Wales; and Astra Pharmaceuticals, Sydney, New South Wales, Australia

Comparison of the risk-benefit profiles of different inhaled glucocorticoids has been limited by inadequate information about the dose-response relationships for efficacy relative to side effects. Fluticasone propionate (FP) is twice as effective as budesonide (BUD), but the potency ratio of FP:BUD with respect to suppression of cortisol production is unknown. The effects of 5 d of treatment with BUD (800, 1,600, and 3,200 µg/d via pMDI) and FP (750, 1,500, and 2,000 µg/d via pMDI) on integrated area under the curve of 24-h plasma cortisol profiles (AUC24h) were compared in a randomized, placebo-controlled, seven-period crossover study in normal male volunteers (n = 28). Plasma cortisol concentrations were measured during the last 24 h of each treatment period. Each treatment (except BUD 800 µg) produced significant dose-dependent reductions in AUC24h compared with placebo; e.g., percent reductions in AUC24h were 23, 41, and 69% for the three doses of BUD, and, correspondingly, 46, 85, and 93% for the three doses of FP. Model-derived measurements of dose potency ratios showed that FP was 2.9 times more potent than BUD in reducing AUC24h (95% CI, 2.5 to 3.5) and 3.1 times more potent in reducing 8:00 A.M. plasma cortisol (95% CI, 2.4 to 4.0). Thus, on a microgram-for-microgram notional dose basis, the systemic effects of a given dose of FP on AUC24h cortisol were equivalent to the effects of three times the dose of BUD.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
J. Holme, J. W. Tomlinson, R. A. Stockley, P. M. Stewart, N. Barlow, and A. L. Sullivan
Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids
Eur. Respir. J., October 1, 2008; 32(4): 1047 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
M. Pujades-Rodriguez, C.J.P. Smith, and R.B. Hubbard
Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease
QJM, August 1, 2007; 100(8): 509 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Masoli, M. Weatherall, S. Holt, P. Shirtcliffe, and R. Beasley
Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis
Eur. Respir. J., November 1, 2006; 28(5): 960 - 967.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Hubbard, A. Tattersfield, C. Smith, J. West, L. Smeeth, and A. Fletcher
Use of inhaled corticosteroids and the risk of fracture.
Chest, October 1, 2006; 130(4): 1082 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. E. Tattersfield, T. W. Harrison, R. B. Hubbard, and K. Mortimer
Safety of Inhaled Corticosteroids
Proceedings of the ATS, November 1, 2004; 1(3): 171 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
L Smeeth, M Boulis, R Hubbard, and A E Fletcher
A population based case-control study of cataract and inhaled corticosteroids
Br. J. Ophthalmol., October 1, 2003; 87(10): 1247 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Rohatagi, V. Arya, K. Zech, R. Nave, G. Hochhaus, B. K. Jensen, and J. S. Barrett
Population Pharmacokinetics and Pharmacodynamics of Ciclesonide
J. Clin. Pharmacol., April 1, 2003; 43(4): 365 - 378.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T W Harrison and A E Tattersfield
Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects
Thorax, March 1, 2003; 58(3): 258 - 260.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
B J LIPWORTH, T HARRISON, A TATTERSFIELD, S A MCKENZIE, T HARRISON, and A TATTERSFIELD
Systemic effects of inhaled steroids
Thorax, December 1, 2001; 56(12): 980b - 981.
[Full Text] [PDF]

Home page
 ThoraxHome page
T W Harrison, A Wisniewski, J Honour, and A E Tattersfield
Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects
Thorax, March 1, 2001; 56(3): 186 - 191.
[Abstract] [Full Text]

Home page
 Eur Respir JHome page
P.L.P. Brand
Inhaled corticosteroids reduce growth. Or do they?
Eur. Respir. J., February 1, 2001; 17(2): 287 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. P. NIELSEN and R. DAHL
Therapeutic Ratio of Inhaled Corticosteroids in Adult Asthma . A Dose-Range Comparison between Fluticasone Propionate and Budesonide, Measuring Their Effect on Bronchial Hyperresponsiveness and Adrenal Cortex Function
Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2053 - 2057.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. P. Nielsen, R. Dahl, E. Derom, and R. Pauwels

Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 2115 - 2115.
[Full Text]

Home page
 ChestHome page
M. Brutsche-Carlen, I. Carlen-Brutsche, and A. Woodcock
Absorption of High-Dose Inhaled Corticosteroids
Chest, May 1, 2000; 117(5): 1526 - 1526.
[Full Text] [PDF]

Home page
 ChestHome page
P. Weiner, N. Berar-Yanay, A. Davidovich, and R. Magadle
Nocturnal Cortisol Secretion in Asthmatic Patients After Inhalation of Fluticasone Propionate
Chest, October 1, 1999; 116(4): 931 - 934.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. J. Dempsey, A. M. Wilson, W. J. R. Coutie, and B. J. Lipworth
Evaluation of the Effect of a Large Volume Spacer on the Systemic Bioactivity of Fluticasone Propionate Metered-Dose Inhaler
Chest, October 1, 1999; 116(4): 935 - 940.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. DEROM, J. VAN SCHOOR, W. VERHAEGHE, W. VINCKEN, and R. PAUWELS
Systemic Effects of Inhaled Fluticasone Propionate and Budesonide in Adult Patients with Asthma
Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 157 - 161.
[Abstract] [Full Text]

Home page
 Arch Intern MedHome page
B. J. Lipworth
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Arch Intern Med, May 10, 1999; 159(9): 941 - 955.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. J Lipworth
Fortnightly review: Modern drug treatment of chronic asthma
BMJ, February 6, 1999; 318(7180): 380 - 384.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society 		  ATS Clinical Skills Tests